Editas Medicine, Inc. (EDIT)

5,32 +0,10 (+1,92%) A partir del 12:11PM EDT. Mercado abierto.

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 265

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Gilmore O'Neill M.D.	President, CEO & Director	1,04M	N/A	1964
Mr. Erick J. Lucera C.F.A., CPA	CFO & Executive VP	911,46k	N/A	1968
Dr. Linda C. Burkly Ph.D.	Executive VP & Chief Scientific Officer	522,44k	N/A	1957
Dr. Baisong Mei M.D., Ph.D.	Executive VP & Chief Medical Officer	654,9k	N/A	1964
Dr. Feng Zhang Ph.D.	Co-Founder & Scientific Advisory Board Member	N/A	N/A	N/A
Dr. George McDonald Church Ph.D.	Co-Founder & Scientific Advisory Board Member	N/A	N/A	1954
Cristi Barnett	Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Charlene Stern J.D., Ph.D.	Executive VP & General Counsel	N/A	N/A	N/A
Ms. Linea Aspesi	Executive VP & Chief People Officer	N/A	N/A	1970
Ms. Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	N/A	N/A	1966

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Editas Medicine, Inc., a día 1 de abril de 2024, es 6. Las puntuaciones base son Auditoría: 2; Tablero: 4; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.